What is William Blair’s Estimate for ZVRA Q1 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Research analysts at William Blair issued their Q1 2026 earnings estimates for Zevra Therapeutics in a research report issued on Wednesday, May 14th. William Blair analyst S. Corwin expects that the company will post earnings per share of ($0.03) for the quarter. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. William Blair also issued estimates for Zevra Therapeutics’ Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.07 EPS and FY2026 earnings at $0.10 EPS.

A number of other equities analysts also recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a report on Thursday, March 13th. JMP Securities set a $18.00 price objective on Zevra Therapeutics in a report on Wednesday, March 12th. Guggenheim increased their target price on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, March 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price target on shares of Zevra Therapeutics in a research note on Wednesday. Finally, Canaccord Genuity Group upped their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $22.29.

Zevra Therapeutics Stock Performance

ZVRA opened at $8.66 on Friday. The stock’s 50 day simple moving average is $7.54 and its 200-day simple moving average is $8.07. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a market cap of $473.52 million, a PE ratio of -4.40 and a beta of 1.87. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $20.40 million during the quarter, compared to analyst estimates of $16.96 million. During the same quarter in the prior year, the business earned ($0.40) earnings per share.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC boosted its stake in shares of Zevra Therapeutics by 292.6% in the 3rd quarter. Barclays PLC now owns 57,599 shares of the company’s stock valued at $399,000 after purchasing an additional 42,926 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Zevra Therapeutics by 54.6% in the 4th quarter. SG Americas Securities LLC now owns 23,500 shares of the company’s stock valued at $196,000 after acquiring an additional 8,302 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Zevra Therapeutics in the fourth quarter valued at about $94,000. Rhumbline Advisers increased its stake in Zevra Therapeutics by 18.4% during the 4th quarter. Rhumbline Advisers now owns 68,053 shares of the company’s stock worth $568,000 after purchasing an additional 10,573 shares in the last quarter. Finally, IFG Advisors LLC increased its position in shares of Zevra Therapeutics by 10.0% during the fourth quarter. IFG Advisors LLC now owns 29,050 shares of the company’s stock worth $242,000 after acquiring an additional 2,650 shares in the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

Insider Activity at Zevra Therapeutics

In related news, Director John B. Bode purchased 10,000 shares of Zevra Therapeutics stock in a transaction that occurred on Wednesday, March 19th. The shares were acquired at an average price of $7.96 per share, for a total transaction of $79,600.00. Following the transaction, the director now directly owns 40,000 shares in the company, valued at approximately $318,400. This represents a 33.33% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 2.40% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.